Lapatinib

Type: Keyphrase
Name: Lapatinib
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Expert Says pCR Data Support Neoadjuvant Therapy in HER2-Positive Breast Cancer

Frankie Ann Holmes, MDSubstantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should ... [Published OncLive - Oct 22 2014]
First reported Oct 20 2014 - Updated Oct 21 2014 - 4 reports

Research and Markets: GSK's Tykerb (lapatinib) HER2-Positive Breast Cancer Treatment Report 2014 - Forecast and Market Analysis to 2023

Research and Markets ( http://www.researchandmarkets.com/research/jklzvb/tykerb ) has announced the addition of the "Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.Click to Continue » ... [Published Fort Mills Times - Oct 20 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Breast Cancer: Signs, Symptoms, and Prevention

Breast cancer is defined as a malignant tumor that starts in the cells of the breast. It is apart of a group of cancer cells that can grow into surrounding tissue and spread to distant areas of the body. The disease usually occurs in women, but men can ... [Published Individual.com - Oct 17 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Chronotherapy, Timing Cancer Drug Treatment For Certain Hours, May Be The Next Wave In Oncology

Chronotherapy is the science of modifying the timing of drugs to achieve the greatest benefit with the lowest risk of side effects. Importantly, a new study from the Weitzmann Institute finds the way our bodies function during the day could interfere ... [Published Medical Daily - Oct 10 2014]
Entities: Lapatinib, Hormone, Oncology
First reported Oct 09 2014 - Updated Oct 10 2014 - 3 reports

Study finds that cancer drugs might work better during sleep

A study published Friday in the journal Nature Communications found that the way people's bodies function during the day could interfere with some cancer medicines.The researchers at the Weitzmann Institute discovered that daytime hormone production "inhibited ... [Published The Week Magazine - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 10 2014 - 2 reports

US Treatment Market for HER2-Positive Breast Cancer to More Than Treble in Value by 2023

A new report from research and consultingfirm GlobalData says that the United States treatment market for humanepidermal growth factor receptor type 2 (HER2) - positive breast cancer willrise more than threefold in value, from $2.41 billion in 2013 to ... [Published MedIndia - Oct 10 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

Share this article:Analysis of results from the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study reinforces findings that support trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer. ALTTO, ... [Published Chemotherapy Advisor - Oct 07 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Methods for the preparation of lapatinib and the salts thereof

Methods for the synthesis of the pharmaceutically active ingredient Lapatinib and the salts thereof are provided. In particular, such methods utilize intermediates in which the hydroxyl function is protected by a tetrahydropyranyl group providing greater ... [Published Free Patents Online - Oct 07 2014]
First reported Oct 06 2014 - Updated Oct 07 2014 - 4 reports

Tumours grow faster at night

Nighttime is the right time for cancer to grow and spread in the body, according to a new study which suggests that administering certain treatments in time with the body's day-night cycle may boost their efficiency.Researchers at the Weizmann Institute ... [Published Business Standard India - Oct 07 2014]
First reported Sep 30 2014 - Updated Oct 01 2014 - 2 reports

For HER2-Positive Breast Cancer, Trastuzumab More Effective Than Lapatinib

the Cancer Therapy Advisor take:According to a new study presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, trastuzumab, a human epidermal growth factor receptor 2 (HER2)-targeted therapy, in combination with ... [Published Chemotherapy Advisor - Sep 30 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

[Correspondence] Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye

Many tyrosine-kinase inhibitors show pH-dependent solubility in the physiologically relevant pH range, which might be susceptible to gastric pH-dependent drug—drug interactions when co-administered with acid-suppressive agents. Such drug-drug interactions ... [Published Lancet Oncology - Oct 01 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 1 reports

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Revision: 20, Authorised

Entities: Tyverb, Lapatinib

Quotes

"Preoperative chemotherapy with trastuzumab and pertuzumab should be considered as a standard of care in all newly diagnosed HER2-positive breast cancers" said Holmes
has released its new PharmaPoint Drug Evaluation report, " ". HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first second-, third, and fourth-line metastatic."
"Sometimes it makes you want to ball up and cry" said Key

More Content

All (68) | News (60) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
GlaxoSmithKline’s third-qtr results not as bad ... [Published Pharma Letter - Oct 22 2014]
Expert Says pCR Data Support Neoadjuvant Therap... [Published OncLive - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Industrial Info Financials - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Indianapolis Business Journal - Oct 22 2014]
HER2 Positive Breast Cancer Drug Market to 2023... [Published Scottrade - Oct 22 2014]
Research and Markets: GSK's Tykerb (lapatinib) ... [Published Fort Mills Times - Oct 20 2014]
Research and Markets: GSK's Tykerb (lapatinib) ... [Published Industrial Info Financials - Oct 20 2014]
Research and Markets: GSK's Tykerb (lapatinib) ... [Published Business Wire Health News - Oct 20 2014]
GSK's Tykerb (lapatinib) HER2-Positive Breast C... [Published Individual.com - Oct 20 2014]
Tykerb (HER2-Positive Breast Cancer) - Forecast... [Published Global Information Inc - Oct 20 2014]
Business notes, October 20 [Published Tyler Morning Telegraph - Oct 20 2014]
Breast Cancer [Published Auto.ru.msn.com - Oct 20 2014]
Breast Cancer: Signs, Symptoms, and Prevention [Published Individual.com - Oct 17 2014]
Lipscomb receives first NIH grant in university... [Published Tennessean - Oct 16 2014]
Tumors Might Grow Faster At Night, Study [Published BioSpace - Oct 16 2014]
OncoTherapy Network Highlights National Breast ... [Published Nasdaq - Oct 15 2014]
OncoTherapy Network Highlights National Breast ... [Published Nation's Restaurant News - Oct 15 2014]
Pathologic Complete Response: Understanding the... [Published The ASCO Post - Oct 15 2014]
Chronotherapy, Timing Cancer Drug Treatment For... [Published Medical Daily - Oct 10 2014]
Study finds that cancer drugs might work better... [Published The Week Magazine - Oct 10 2014]
US Treatment Market for HER2-Positive Breast Ca... [Published MedIndia - Oct 10 2014]
Why Cancer Drugs May Work Better While You Sleep [Published Real Clear Politics - TIME.com - Oct 09 2014]
Why Cancer Drugs May Work Better While You Sleep [Published TIME.com - Oct 09 2014]
Cancer Drugs Fund in England: Plugging a Gap in... [Published American Journal of Public Health - Oct 09 2014]
New Breast Cancer Study Findings Have Been Repo... [Published Pharmacy Choice - Oct 09 2014]
Are cancer drugs too expensive? Maybe. [Published American Council On Science & Health - Oct 08 2014]
New Tactics Needed for Adjuvant Therapy to Adva... [Published OncLive - Oct 08 2014]
Tumors may grow faster at night, Israeli study ... [Published The Times Of Israel - Oct 08 2014]
Adjuvant Lapatinib and/or Trastuzumab Treatment... [Published Chemotherapy Advisor - Oct 07 2014]
Methods for the preparation of lapatinib and th... [Published Free Patents Online - Oct 07 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: GSK's Tykerb (lapatinib) ... [Published Business Wire Health News - Oct 20 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jklzvb/tykerb) has announced the addition of the "Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering. GSK's Tykerb ...
Why Cancer Drugs May Work Better While You Sleep [Published Real Clear Politics - TIME.com - Oct 09 2014]
It’s news to no one that your body works differently when you’re awake and when you’re sleeping. But could the different states also affect how your body processes certain life-saving drugs? Researchers, reporting Friday in the journal Nature Communications, ...
Why Cancer Drugs May Work Better While You Sleep [Published TIME.com - Oct 09 2014]
It’s news to no one that your body works differently when you’re awake than when you’re sleeping. But could the different states also affect how your body processes certain life-saving drugs? Researchers, reporting Friday in the journal Nature Communications, ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Sep 29 2014]
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
Yet another entry in the "Why do people keep investing in biopharma?" files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.